-
Information-Publications
-
Discovery of a potent and selective proteolysis targeting chimera (PROTAC) degrader of NSD3 histone methyltransferaseDetails
-
Dual guide RNA-mediated concurrent C&G-to-T&A and A&T-to-G&C conversions using CRISPR base editorsDetails
-
TET2 suppresses VHL deficiency-driven clear cell renal cell carcinoma by inhibiting HIF signalingDetails
-
Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBDDetails
-
Creatine kinase brain-type regulates BCAR1 phosphorylation to facilitate DNA damage repairDetails
-
Base editing‐mediated perturbation of endogenous PKM1/2 splicing facilitates isoform‐specific functional analysis in vitro and in vivoDetails
-
"Heyuan Liji" is a joint venture between Heyuan Biotechnology (stock code: 688238) and Liji Biotechnology, specializing in the "Liji Biotechnology" and "Life-ilab" reagent brands